HOOKIPA Pharma's HB-200 (eseba-vec) demonstrates encouraging results in clinical trials for HPV16-positive head and neck cancers, addressing a significant unmet medical need.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.